These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21178942)

  • 1. IGF-1 abuse in sport: clinical and medico-legal aspects.
    Molinelli A; Bonsignore A; Cicconi M; Cioè A; Traverso A
    J Sports Med Phys Fitness; 2010 Dec; 50(4):530-5. PubMed ID: 21178942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Use Exemptions.
    Gerrard D; Pipe A
    Med Sport Sci; 2017; 62():55-67. PubMed ID: 28571022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Medication, athletes and doping regulations].
    Hartgens F
    Ned Tijdschr Geneeskd; 2008 Aug; 152(33):1844-8. PubMed ID: 18783164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of prohibited substances for therapeutic reasons in athletes affected by endocrine diseases and disorders: the therapeutic use exemption (TUE) in clinical endocrinology.
    Di Luigi L; Pigozzi F; Sgrò P; Frati L; Di Gianfrancesco A; Cappa M
    J Endocrinol Invest; 2020 May; 43(5):563-573. PubMed ID: 31734891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Between medical treatment and performance enhancement: an investigation of how elite athletes experience Therapeutic Use Exemptions.
    Overbye M; Wagner U
    Int J Drug Policy; 2013 Nov; 24(6):579-88. PubMed ID: 23582632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IGF-I abuse in sport.
    Guha N; Dashwood A; Thomas NJ; Skingle AJ; Sönksen PH; Holt RI
    Curr Drug Abuse Rev; 2009 Sep; 2(3):263-72. PubMed ID: 20443773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Medicolegal aspects of doping in sports].
    Pruvost J; Depiesse F
    Ann Readapt Med Phys; 2004 Aug; 47(6):263-73. PubMed ID: 15297116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The world anti-doping program and the primary care physician.
    Hilderbrand RL
    Pediatr Clin North Am; 2007 Aug; 54(4):701-11, x-xi. PubMed ID: 17723872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Growth hormone and IGF-1 as doping agents in competitive sport].
    Jóźków P; Medraś M
    Endokrynol Pol; 2009; 60(5):389-94. PubMed ID: 19885810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor-I (IGF-I) misuse in athletes and potential methods for detection.
    Guha N; Cowan DA; Sönksen PH; Holt RI
    Anal Bioanal Chem; 2013 Dec; 405(30):9669-83. PubMed ID: 23934394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Athlete Biological Passport: an integral element of innovative strategies in antidoping.
    Vernec AR
    Br J Sports Med; 2014 May; 48(10):817-9. PubMed ID: 24659508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of the legal framework applicable to the marker method for the detection of human growth hormone.
    Young RR; Bielak JS; Horvitz SL
    Growth Horm IGF Res; 2009 Aug; 19(4):366-8. PubMed ID: 19608446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The necessary dialogue between medicine and anti-doping for the integrity of sport and the athlete].
    Faiss R; Salamin O; Astolfi T; Saugy M
    Rev Med Suisse; 2018 Jul; 14(613):1360-1363. PubMed ID: 29998639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of growth hormone (GH)-dependent markers in the detection of GH abuse in sport: Physiological intra-individual variation of IGF-I, type 3 pro-collagen (P-III-P) and the GH-2000 detection score.
    Erotokritou-Mulligan I; Eryl Bassett E; Cowan DA; Bartlett C; Milward P; Sartorio A; Sönksen PH; Holt RI
    Clin Endocrinol (Oxf); 2010 Apr; 72(4):520-6. PubMed ID: 19650783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IGF-I abuse in sport: current knowledge and future prospects for detection.
    Guha N; Sönksen PH; Holt RI
    Growth Horm IGF Res; 2009 Aug; 19(4):408-11. PubMed ID: 19467615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene doping.
    Haisma HJ; de Hon O
    Int J Sports Med; 2006 Apr; 27(4):257-66. PubMed ID: 16572366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone abuse in sports: the antidoping perspective.
    Barroso O; Mazzoni I; Rabin O
    Asian J Androl; 2008 May; 10(3):391-402. PubMed ID: 18385901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls.
    Thevis M; Thomas A; Geyer H; Schänzer W
    Growth Horm IGF Res; 2014 Dec; 24(6):276-80. PubMed ID: 25466910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. rhGH Abuse for Sports Performance.
    Rogol AD
    Pediatr Endocrinol Rev; 2018 Sep; 16(Suppl 1):142-149. PubMed ID: 30378792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoassays for the measurement of IGF-II, IGFBP-2 and -3, and ICTP as indirect biomarkers of recombinant human growth hormone misuse in sport. Values in selected population of athletes.
    Abellan R; Ventura R; Palmi I; di Carlo S; Bacosi A; Bellver M; Olive R; Pascual JA; Pacifici R; Segura J; Zuccaro P; Pichini S
    J Pharm Biomed Anal; 2008 Nov; 48(3):844-52. PubMed ID: 18617352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.